Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: Study protocol for a cluster randomised controlled trial

Trials

Volumn 17, Issue 1, 2016, Pages

  Roberts, Kirsty ^a   Macleod, John ^a   Metcalfe, Chris ^a,b   Simon, Joanne ^a,b   Horwood, Jeremy ^a,b   Hollingworth, William ^a   Marlowe, Sharon ^c   Gordon, Fiona H ^c   Muir, Peter ^d   Coleman, Barbara ^e   Vickerman, Peter ^a   Harrison, Graham I ^f   Waldron, Cherry Ann ^a,g   Irving, William ^f   Hickman, Matthew ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e Public Health Commissioning and Performance   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Case finding; Complex intervention; HCV; Hepatitis C; Primary care; RCT

Indexed keywords

ALGORITHM; ARTICLE; AWARENESS; CASE FINDING; CLINICAL ASSESSMENT; CLINICAL AUDIT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; ELECTRONIC PATIENT RECORD; ENGLAND; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH ECONOMIC MODEL; HEALTH EDUCATION; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFORMATION DISSEMINATION; INTERVENTION COST; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; NONBIOLOGICAL MODEL; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT REFERRAL; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SEMI STRUCTURED INTERVIEW; STATISTICAL ANALYSIS; WAITING ROOM; WORK EXPERIENCE; CHRONIC HEPATITIS C; PATIENT EDUCATION; PRIMARY HEALTH CARE;

CLINICAL PROTOCOLS; HEPATITIS C, CHRONIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION AS TOPIC; PRIMARY HEALTH CARE; REFERRAL AND CONSULTATION;

EID: 84984643574     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1501-3     Document Type: Article

References (24)

1. Williams R, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958):1953-97.
2. Seeff LB. The history of the 'natural history' of hepatitis C (1968-2009). Liver Int. 2009;29 Suppl 1:89-99.
3. Harris RJ, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health. 2012;22(2):187-92.
4. Martin NK, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol. 2011;54(6):1137-44.
5. Cullen BL, et al. Identifying former injecting drug users infected with hepatitis C: an evaluation of a general practice-based case-finding intervention. J Public Health (Oxf). 2012;34(1):14-23.
6. NICE. Hepatitis B and C - ways to promote and offer testing to people at risk of infection. 2012. Retrieved from Manchester: http://guidance.nice.org.uk/PHG/Wave22/3.
7. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P. Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open. 2013;3(8). doi: 10.1136/bmjopen-2013-003153.
8. Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. Am J Prev Med. 2014;47(3):233-41.
9. Coffin PO, et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54(9):1259-71.
10. Helsper C, et al. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care. Br J Gen Pract. 2012;62(596):e212-6.
11. Wolffram I, et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol. 2015;62(6):1256-64.
12. Vriend HJ, et al. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141(6):1310-7.
13. Hickman M, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf). 2009;31(3):374-82.
14. Sweeting MJ, De Angelis D, Ades AE, Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stat Methods Med Res. 2008;18(4). doi: 10.1177/0962280208094704.
15. Jones HE, Welton NJ, Ades AE, Pierce M, Davies W, Coleman B, Millar T, Hickman M. Problem drug use prevalence estimation revisited: heterogeneity in capture-recapture and the role of external evidence. Addiction. 2016;111(3):438-47.
16. Heart UK. Systematically Identifying Familial Hypercholesterolaemia in Primary Care, in An Audit within the Medway Clinical Commissioning Group. 2014. https://heartuk.org.uk/files/uploads/09-14_HEART_UK_Medway_report.pdf.
17. Unit, PSSR. Personal Social Services Research Unit. Unit costs of health and social care 2014. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2015/index.php.
18. Department of Health. Reference costs 2013-2014. November 2014. https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014.
19. Sculpher M. Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. Fam Pract. 2000;17 Suppl 1:S26-31.
20. Wright M, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10(21):1-113. iii.
21. Martin NK. Assessing the cost-effectiveness of interventions aimed at promoting and offering hepatitis C testing to injecting drug users: an economic modelling report. 2012.
22. Thompson CJ, Castelnuovo E, Pitt M, Cramp M, Siebert U, Stein K. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract. 2006;23(4):393-406.
23. Sandelowski M. Sample size in qualitative research. Res Nurs Health. 1995;18(2):179-83.
24. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101.